Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study |
| |
Authors: | Gypsyamber D’Souza PhD Sakshi R. Tewari MHS Tanya Troy MPH Tim Waterboer PhD Linda Struijk PhD Rachel Castillo MHS Hannah Wright BA Michael Shen BS Brett Miles MD Mattias Johansson PhD Hilary A. Robbins PhD Carole Fakhry MD |
| |
Affiliation: | 1. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA;2. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medicine, Baltimore, Maryland, USA;3. Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany;4. Viroclinics-DDL Diagnostic Laboratory, Rijswijk, Netherlands;5. Department of Otolaryngology-Head and Neck Surgery, Northwell Health, New York, New York, USA;6. Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France |
| |
Abstract: | Background Human papillomavirus (HPV)-related oropharyngeal cancer screening is being explored in research studies, but strategies to identify an appropriate population are not established. The authors evaluated whether a screening population could be enriched for participants with oncogenic HPV biomarkers using risk factors for oral HPV. Methods Participants were enrolled at Johns Hopkins Hospitals and Mount Sinai Icahn School of Medicine. Eligible participants were either men aged 30 years or older who had two or more lifetime oral sex partners and a personal history of anogenital dysplasia/cancer or partners of patients who had HPV-related cancer. Oral rinse and serum samples were tested for oncogenic HPV DNA, RNA, and E6 or E7 antibodies, respectively. Participants with any biomarker were considered at-risk. Results Of 1108 individuals, 7.3% had any oncogenic oral HPV DNA, and 22.9% had serum antibodies for oncogenic HPV E6 or E7. Seventeen participants (1.5%) had both oral and blood biomarkers. HPV type 16 (HPV16) biomarkers were rarer, detected in 3.7% of participants, including 20 with oral HPV16 DNA and 22 with HPV16 E6 serum antibodies (n = 1 had both). In adjusted analysis, living with HIV (adjusted odds ratio, 2.65; 95% CI, 1.60–4.40) and older age (66–86 vs. 24–45 years; adjusted odds ratio, 1.70; 95% CI, 1.07–2.70) were significant predictors of being at risk. Compared with the general population, the prevalence of oral HPV16 (1.8% vs. 0.9%), any oncogenic oral HPV DNA (7.3% vs. 3.5%), and HPV16 E6 antibodies (2.2% vs. 0.3%) was significantly elevated. Conclusions Enrichment by the eligibility criteria successfully identified a population with higher biomarker prevalence, including HPV16 biomarkers, that may be considered for screening trials. Most in this group are still expected to have a low risk of oropharyngeal cancer. |
| |
Keywords: | antibody biomarker human papillomavirus (HPV) oropharyngeal cancer (OPC) oral sex screening |
|
|